glp-1 drugs shortage Drug Shortages The weight loss drug shortage
Description
Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof
Heres what evidence says about absorption and claims, plus safety checks and questions to ask your clinician.
New analyses involving more than 100,000 patients suggest that users of popular diabetes and weight-loss medications face a lower risk of developing certain cancers and a reduced risk of metastasis.
Using a global dataset and propensity matching, they found significantly lower mortality rates, major cardiovascular events (MACEs), and adverse kidney outcomes (MAKEs) among GLP-1 RA users compared to non-users
Click for this HIMS stock update.
Conclusions/interpretation Our findings do not support an increased risk of SIS when taking GLP-1RA in individuals with type 2 diabetes and obesity
